Presentation is loading. Please wait.

Presentation is loading. Please wait.

Relationship between urinary TNF-α and RANTES excretion

Published byΚέφαλος Ταμτάκος Modified over 5 years ago

Similar presentations

Presentation on theme: "Relationship between urinary TNF-α and RANTES excretion"— Presentation transcript:

1 Relationship between urinary TNF-α and RANTES excretion
Relationship between urinary TNF-α and RANTES excretion. □, Determinations during periods when the patients were not receiving MMF (pre- and posttreatment periods); ▪, determinations during MMF treatment. Relationship between urinary TNF-α and RANTES excretion. □, Determinations during periods when the patients were not receiving MMF (pre- and posttreatment periods); ▪, determinations during MMF treatment. Jose Herrera et al. JASN 2006;17:S218-S225 ©2006 by American Society of Nephrology

Download ppt "Relationship between urinary TNF-α and RANTES excretion"

Similar presentations

Urea and nitrogen excretion in pediatric peritoneal dialysis patients

Urea and nitrogen excretion in pediatric peritoneal dialysis patients
Compared with irbesartan, there was a greater reduction in UP/C with sparsentan, and a larger proportion of patients achieved FPRE. The figure illustrates.

Compared with irbesartan, there was a greater reduction in UP/C with sparsentan, and a larger proportion of patients achieved FPRE. The figure illustrates.
Patient disposition for the double-blind study period.

Patient disposition for the double-blind study period.
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Histomorphology in a case of mixed (cellular and humoral) acute kidney allograft rejection (patient 10). Histomorphology in a case of mixed (cellular and.

Histomorphology in a case of mixed (cellular and humoral) acute kidney allograft rejection (patient 10). Histomorphology in a case of mixed (cellular and.
Key amino acid positions identified by association analysis are highlighted in three-dimensional ribbon models for the HLA-DR, HLA-DQ, HLA-A and HLA-DP.

Key amino acid positions identified by association analysis are highlighted in three-dimensional ribbon models for the HLA-DR, HLA-DQ, HLA-A and HLA-DP.
Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.

Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.
Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.

Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.
Relationship between SBP levels and the urinary excretion of TNF-α (A), RANTES (B), and thiobarbituric acid–reacting substances (malondialdehyde [MDA];

Relationship between SBP levels and the urinary excretion of TNF-α (A), RANTES (B), and thiobarbituric acid–reacting substances (malondialdehyde [MDA];
Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase.

Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase.
Missense mutations in TNXB as a cause of VUR

Missense mutations in TNXB as a cause of VUR
Studies reporting the incident rate for ischemic steal syndrome per 1000 patient days. Studies reporting the incident rate for ischemic steal syndrome.

Studies reporting the incident rate for ischemic steal syndrome per 1000 patient days. Studies reporting the incident rate for ischemic steal syndrome.
Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.

Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.
Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF

Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF
Pedigrees of the families of patients 1 and 2 show that the clinical phenotype co-segregates with compound heterozygous CLDN10 variants. Pedigrees of the.

Pedigrees of the families of patients 1 and 2 show that the clinical phenotype co-segregates with compound heterozygous CLDN10 variants. Pedigrees of the.
Both patient 1 and her family members showed a normal physiological AQP2 response to DDAVP. Immunoblotting for AQP2 was performed on urinary exosomes derived.

Both patient 1 and her family members showed a normal physiological AQP2 response to DDAVP. Immunoblotting for AQP2 was performed on urinary exosomes derived.
Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.

Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.
Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.

Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.
Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.
T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.

T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.

Similar presentations

Ads by Google